Trubion Announces Initiation Of Phase 2b Study Of TRU 015 For The Treatment Of Rheumatoid Arthritis
May 15th 2008Drug InformationArthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced that its partner, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has commenced patient dosing in the next Phase 2b clinical trial of TRU-015 in patients with rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing TRU-015, SBI-087 and other CD20-directed products.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
